Day One Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DAWN research report →
About the company
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma.
- CEO
- Jeremy Bender
- IPO
- 2021
- Employees
- 181
- HQ
- Brisbane, CA, US
Price Chart
- Market Cap
- $2.22B
- P/E
- -20.70
- P/S
- 14.06
- P/B
- 5.05
- EV/EBITDA
- -19.24
- Div Yield
- 0.00%
- Gross Margin
- 89.12%
- Op Margin
- -80.76%
- Net Margin
- -67.85%
- ROE
- -23.43%
- ROIC
- -28.03%
- Revenue
- $158.18M · 20.60%
- Net Income
- $-107,322,000 · -12.38%
- EPS
- $-1.04 · -1.96%
- Op Income
- $-127,750,000
- FCF YoY
- -29.64%
- 52W High
- $21.53
- 52W Low
- $5.63
- 50D MA
- $18.21
- 200D MA
- $10.72
- Beta
- -1.75
- Avg Volume
- 4.01M
Get TickerSpark's AI analysis on DAWN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | AI Day1 LLC | other | 12,929,322 |
| Apr 23, 26 | AI Day1 LLC | sell | 827,586 |
| Apr 23, 26 | Bender Jeremy | sell | 808,285 |
| Apr 23, 26 | Bender Jeremy | sell | 286,000 |
| Apr 23, 26 | Bender Jeremy | sell | 355,000 |
| Apr 23, 26 | Bender Jeremy | sell | 222,188 |
| Apr 23, 26 | VASCONCELLES MICHAEL | sell | 4,397 |
| Apr 23, 26 | VASCONCELLES MICHAEL | sell | 346,000 |
| Apr 23, 26 | VASCONCELLES MICHAEL | sell | 171,000 |
| Apr 23, 26 | VASCONCELLES MICHAEL | sell | 106,875 |
Our DAWN coverage
Recent articles, reports, and earnings notes.
No research on DAWN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DAWN report →Similar companies
Peers in the same neighborhood.